Use of elexacaftor/tezacaftor/ivacaftor combination in pregnancy.

Giuseppe CiminoSara SorrentiManuel MurcianoPaola GaloppiFiorentina AscenzioniBruno BottaRoberto Brunellinull null

Published in: Archives of gynecology and obstetrics (2023)

Thus, despite the lack of evidence on the topic, the use of Elexacaftor/Tezacaftor/Ivacaftor in pregnancy seems to be apparently not associated with major adverse events, thus opening optimistic scenarios in terms of management of these patients.

Keyphrases

cystic fibrosis
end stage renal disease
preterm birth
ejection fraction
newly diagnosed
chronic kidney disease
climate change
pregnancy outcomes
peritoneal dialysis
pregnant women
patient reported